Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. Goldstein LJ, et al. Among authors: swaby rf. Breast Cancer Res Treat. 2017 Sep;165(2):375-382. doi: 10.1007/s10549-017-4310-9. Epub 2017 Jun 16. Breast Cancer Res Treat. 2017. PMID: 28623430 Free PMC article. Clinical Trial.
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, Sparano JA. Ramaswamy B, et al. Breast Cancer Res Treat. 2012 Apr;132(3):1063-72. doi: 10.1007/s10549-011-1928-x. Epub 2011 Dec 27. Breast Cancer Res Treat. 2012. PMID: 22200869 Free PMC article. Clinical Trial.
Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer.
Freedman GM, Anderson PR, Bleicher RJ, Litwin S, Li T, Swaby RF, Ma CM, Li J, Sigurdson ER, Watkins-Bruner D, Morrow M, Goldstein LJ. Freedman GM, et al. Among authors: swaby rf. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):888-93. doi: 10.1016/j.ijrobp.2012.01.091. Epub 2012 May 12. Int J Radiat Oncol Biol Phys. 2012. PMID: 22580118 Free PMC article. Clinical Trial.
Impact of the radiation boost on outcomes after breast-conserving surgery and radiation.
Murphy C, Anderson PR, Li T, Bleicher RJ, Sigurdson ER, Goldstein LJ, Swaby R, Denlinger C, Dushkin H, Nicolaou N, Freedman GM. Murphy C, et al. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):69-76. doi: 10.1016/j.ijrobp.2010.04.067. Epub 2010 Aug 21. Int J Radiat Oncol Biol Phys. 2011. PMID: 20732766 Free PMC article.
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.
Freedman GM, Anderson PR, Goldstein LJ, Ma CM, Li J, Swaby RF, Litwin S, Watkins-Bruner D, Sigurdson ER, Morrow M. Freedman GM, et al. Among authors: swaby rf. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):347-53. doi: 10.1016/j.ijrobp.2006.12.035. Epub 2007 Mar 26. Int J Radiat Oncol Biol Phys. 2007. PMID: 17379430 Clinical Trial.
46 results